Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid 'reactive depression' in an adolescent

15Citations
Citations of this article
98Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the United States, duloxetine has been approved for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and fibromyalgia in the adult population. Data regarding the use of duloxetine in the pediatric population, however, are very limited. Femoral nerve injury is a rare complication of cardiac catheterization. In the case described, duloxetine contributed to a successful multimodal treatment program for peripheral neuropathic pain due to femoral neuropathy in an adolescent with 'reactive depression' and conversion symptoms. To the best of the authors' knowledge, the present article is only the third such report on this dual use of duloxetine in children and adolescents, and the first report of such treatment following femoral neuropathy induced by cardiac catheterization. ©2011 Pulsus Group Inc. All rights reserved.

Cite

CITATION STYLE

APA

Kachko, L., Ami, S. B., Liberman, A., Birk, E., & Kronenberg, S. (2011). Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid “reactive depression” in an adolescent. Pain Research and Management, 16(6), 457–459. https://doi.org/10.1155/2011/164984

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free